Valneva is a specialty vaccine company providing prevention against diseases with major unmet medical needs. The Company has a growing commercial business with two successful vaccines for travelers. Our focused pipeline includes the only Lyme disease vaccine candidate in clinical development today and the only single-shot chikungunya vaccine candidate.
Valneva at a glance
Successful commercial vaccines for travelers
€M
Product sales revenues exceeded1,2
Clinical programs
Specialized
Travel vaccines
Vector-transmitted diseases
Focused
On innovative vaccines for unmet medical needs
Steadily Growing
Added over 200 employees since 20133
- As a result of the merger in May 2013 between Intercell AG and Vivalis SA to form Valneva SE, the Company’s 2018 and 2013 results are not fully comparable. Vivalis SA’s results were fully included in the income statement of 2013 while Intercell’s results were only included for the seven-month period starting from June 2013
- Including service revenues and license fees
- As of December 31, 2018